Eisai Co Ltd (EII.BE)
| Previous close | 35.97 |
| Open | 35.22 |
| Bid | 35.17 x 0 |
| Ask | 35.31 x 0 |
| Day's range | 35.22 - 35.22 |
| 52-week range | 35.22 - 71.44 |
| Volume | |
| Avg. volume | 2 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireEisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai submitted to the U.S. Food and Drug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with
Yahoo FinanceAlzheimer's drug Leqembi: The twice-monthly infusion could be available in injection form
An Alzheimer's drug in injectable form could be the key for Biogen, Eisai to ease pressures and concerns of a limited market and revenue.
- Yahoo Finance Video
Eisai reporting positive data on injectable Alzheimer’s drug
Japanese pharma company Eisai (ESAIY) reported positive results in clinical trials of its Alzheimer’s drug Leqembi. This could mean a revolution for administering the drug, which is currently only administered via IV. Yahoo Finance’s Anjalee Khemlani breaks down what this means in terms of access and costs as concerns about side effects and formularies are evident. Pfizer (PFE) and BioNTech (BNTX) are also working together to develop a combo COVID-flu vaccine, showing positive data in its trial. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
